期刊文献+

联合利血平和MPTP制备小鼠帕金森病模型的实验研究 被引量:3

Experimental study on Parkinson disease model induced by reserpine plus MPTP in C57BL mice
暂未订购
导出
摘要 目的探讨联合应用利血平和1-甲基-4-苯基-1,2,3,6四氢吡啶(1-methyl-4-phenyl-tetrahydropyridine,MPTP)制备帕金森病小鼠模型的方法。方法采用单独应用利血平、MPTP及联合利血平和MPTP分别造成C57BL小鼠的帕金森病模型,对照组用同体积的生理盐水,测定各组小鼠爬杆时间检测动物运动协调性,应用免疫组织化学方法观察囊泡单胺转运体(VMAT2)和酪胺酸羟化酶(TH)在黑质致密部分布的变化。结果所有帕金森病模型小鼠都出现不同程度爬杆时间延长,免疫组织化学分析显示,帕金森病组小鼠较对照组小鼠VMAT2和TH阳性神经元细胞数目在黑质致密部明显减少。联合利血平和MPTP制备的C57BL小鼠帕金森病模型较利血平或MPTP诱导模型在病理和行为变化更为明显。结论联合应用利血平和MPTP是一种有效的制备帕金森病小鼠模型的方法。 Objective To investigate the feasibility of reserpine plus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP) to induce Parkinson disease( PD) mouse models. Methods C57BL mice were given reserpine, MPTP, or reserpine + MPTP to induced PD model,respectively. The control mice were treated with the same amount of 0.9% saline. The pole test was conducted to determine the motor harmony,and the distribution of VMAT2 and TH in substantia nigra pars compacta(SNC) was examined by immunohistoehemical staining. Results All PD model mice showed a different degree of disability in pole test. The numbers of VMAT2-positive neurons and TH-positive neurons in SNC were significantly reduced in PD models than in the controls. Changes of pathology and behavior features in PD models by reserpine plus MPTP were more obviously than that by reserpine or MPTP. Conclusion Reserpine plus MPTP may be an effective way to induce C57BL mouse model of PD.
出处 《山西医科大学学报》 CAS 2009年第8期693-696,767,共5页 Journal of Shanxi Medical University
关键词 帕金森病 动物模型 利血平 1-甲基-4-苯基-1 2 3 6-四氢吡啶 Parkinson disease animal models reserpine 1 -methyl-4-phenyl- 1,2,3,6-tetrahydropyridine
  • 相关文献

参考文献11

  • 1Kopin IJ, Markey SP. MPTP toxicity:implication for research in Parkinson's disease [ J ]. Annu Rev Neurosci, 1988,11:81 - 96.
  • 2Jakowec MW, Petzinger GM. 1 -methyl-d-phenyl-1,2,3,6-tetrahy- dropyridine lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates [ J ]. Comp Med, 2004,54 ( 5 ) : 497 -513.
  • 3Shimoji M ,Zhang L, Mandir AS ,et al. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease[ J]. Brain Res Mol Brain Res,2005,134 (1) :103 -108.
  • 4Markey SP,Johannessen JN, Chiueh CC,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism [ J]. Nature, 1984,311:464 -467.
  • 5Staal RG, Sonsalla PK. Inhibition of brain vesicular monoamine transporter ( VMAT2 ) enhances 1-Methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata [ J ]. J Pharmacol Exp Ther, 2000,293:336 - 342.
  • 6田向阳,丁新生,闵敏,孙兴珍.囊泡单胺转运体在人胚胎脑组织中的分布特征及其与帕金森病的关系[J].临床神经病学杂志,2008,21(4):270-272. 被引量:2
  • 7田向阳,丁新生,董海蓉.囊泡单胺转运体在帕金森病小鼠脑组织中的分布特征[J].南京医科大学学报(自然科学版),2004,24(3):246-249. 被引量:4
  • 8Mitchell IJ,Lawson S, Moser B,et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the Parkinsonian rat[ J]. Neuroscience, 1994,63 : 1 - 7.
  • 9Darcben F, Scherman, Henry JP. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter[ J ]. Biochemistry, 1989,28 : 1692 - 1697.
  • 10Merickle A, Edwerd RH. Transport of histamine by Vesicular Monoamine Transporter-2 [ J ]. Neuropharmacol, 1995,34 : 1543 - 1547.

二级参考文献16

  • 1[2]Peter D,Jimenez J,Liu Y,et al.The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors[J].J Biol Chem,1994,269:7231.
  • 2[3]Speciale SG.MPTP insights into parkinsonian neurodegeneration[J].Neurotoxicol Teratol,2002,24:607.
  • 3[4]Liu YJ,Peter D,Roghani A,et al.A cDNA that suppresses MPP+ toxicity encodes a vesicular monoamine transporter[J].Cell,1992,70:539.
  • 4[5]Fumagalli F,Gainetdinov RR,Wang YM,et al.Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knockout mice[J].J Neurosci,1999,19:2424.
  • 5[6]Miller GW,Erickson JD,Perez JD,et al.Immunochemical analysis of vesicular monoamine transporter protein in Parkinson′s disease[J].Experimental Neurology,1999,156:138.
  • 6Speciale SG. MPTP insights into parkinsonian neurodegeneration[J]. Neurotoxicology and Teratology, 2002, 24:607-620.
  • 7Buck KJ, Amara SG. Chimeric dopamine-norepinephrine transporters delineste structural domains influencing selectivity for catecholamine and 1-methyl-4-phenylpyridinium [J]. Proc Natl Acad Sci USA, 1994, 91:12584-12588.
  • 8Liu YJ, Doris Peter, All Roghani, et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular monoamine transporter[J]. Cell, 1992, 70:539-551.
  • 9Peter Vieregge, Manuel B, Graeber. Role of mitochondria in Parkinson disease[J]. Biol Chem, 1999, 380:865-870.
  • 10Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter protein in Parkinsons disease[J]. Exp Neurology. 1999, 156:138-148.

共引文献4

同被引文献52

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部